PFAPA Research Articles

PFAPA syndrome: a case report of a challenging diagnosis

Introduction: PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis) is the most common cause of periodic fever in childhood. Typically, it occurs in children up to five years old and is characterized by sudden and recurrent episodes of high-spiking fever accompanied by at least one of the other eponymous features. This case report enhances the importance of its recognition, to prevent unnecessary tests and/or treatments. Case description: We present a case of a four-year-old boy, with no relevant background, observed multiple times in primary and secondary care settings due to fever. His parents reported monthly episodes of high fever, usually along with pharyngitis, oral aphthosis, and/or cervical adenitis. He was completely asymptomatic between crises and showed normal growth and psychomotor development. Several oropharyngeal and nasal swab tests were performed, with negative results. After some investigation and articulation with his pediatrician, a diagnosis of PFAPA syndrome was made and he started oral corticosteroids, a single dose on the first day of every episode, obtaining fast and complete symptomatic relief. Comment: PFAPA syndrome diagnosis is challenging, and its process can trigger anxiety in the patient, his family, and even in healthcare professionals. However, this relatively common and benign condition tends to be self-limited, usually with spontaneous resolution before adolescence. Its recognition by the medical community is essential, particularly in primary care settings since family physicians are usually the first point of medical contact within the healthcare system. This case report enhances the family physician’s core competence to manage illness with nonspecific presentations and the importance of the interface with other specialties to provide the best care to the community.

PFAPA syndrome: a case report

Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome is a complex autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammatory features. It is usually a disease of children but adult onset has also been reported. The common clinical features are aphthous stomatitis, cervical lymphadenitis, pharyngitis etc with exclusion of upper respiratory tract infection and cyclic neutropenia. The patient remains completely asymptomatic between the episodes of these clinical features with normal growth and development. Here we report a case of 20-year-old male who presented with features suggestive of PFAPA syndrome and well responded with a single dose of high dose prednisolone. BIRDEM Med J 2024; 14(3): 161-165

PFAPA Syndrome: Evaluation of Clinical Findings, Immunological Alterations, and Treatment Approaches

PFAPA Syndrome: Evaluation of Clinical Findings, Immunological Alterations, and Treatment Approaches

Paediatric PFAPA Syndrome: an Easily Missed Diagnosis

Paediatric PFAPA Syndrome: an Easily Missed Diagnosis

The role of the tonsils in the genesis of PFAPA syndrome: a modern view and description of two clinical cases

In ENT clinical practice, there are cases of a disease similar to those ones of chronic adenotonsillitis, but insensitive to the designated conservative therapy. This disease was first described in 1987 and is called PFAPA syndrome. Its symptoms periodicity and its regression when corticosteroids are prescribed were established. Adenotomy/adenotonsillectomy can eliminate the symptoms of the disease or significantly reduce the frequency of relapses. The histological features of the structure of the palatine and pharyngeal tonsils, as well as the characteristics of the PFAPA-syndrome, were revealed. Clinical Case Description: patient K., 3 years old, repeated cases of fever were recorded in the child from the age of 1 year 3 months. They were initially regarded as manifestations of acute respiratory viral infections, complicated by adenoiditis, pharyngitis, aphthous stomatitis and cervical lymphadenitis, with a frequency of 1.5–2 months, 6–7 episodes per year. The antiviral therapy was prescribed without any effect. A prednisolone test (1.5 mg/kg) was positive; it led to a rapid normalization of body temperature and condition improvement. The adenotonsillectomy was done. Surgical intervention and the postoperative period were uneventful. The follow-up period was without any recurrence of the disease for more than 1 year. Patient F., 6 years old, had, the recurrent (each 1.5–2 months), acute respiratory viral infections, adenotonsillitis, accompanied by lymphadenitis and febrile fever. A prednisolone test was positive. The patient was diagnosed with PFAPA syndrome by the age of 6. The adenotonsillectomy was done. No disease relapses were noted in the follow-up.

Effect of Colchicine Treatment on Clinical Course in Children with PFAPA Syndrome.

Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome (PFAPA) is the most common periodic fever condition in children. There is no consensus on treatment to prevent attacks and reduce their frequency. In this study, we aimed to evaluate the effectiveness of colchicine treatment in PFAPA syndrome. In addition, we described the demographic and clinical features of PFAPA patients. We retrospectively analyzed 58 PFAPA patients who were started on colchicine treatment between January 2017 and January 2022. Demographic data, clinical features, laboratory tests, genetic analysis of MEditerranean FeVer (MEFV) mutations, and autoinflammatory disease activity index (AIDAI) scores of all patients were evaluated. In addition, patients were divided into two groups according to MEFV variants and compared. Attack frequency, duration, and AIDAI scores decreased in all patients after colchicine treatment. Duration of follow-up was 13.53±6.65 months. The median±IQR age at diagnosis was 3.2 (2-5) years. Thirty three (56.9%) patients had heterozygous mutations of MEFV. The most common MEFV variants were M694V (63.6%). There was no significant difference between the two groups in terms of colchicine responses. Colchicine treatment is effective and safe in patients with PFAPA who have frequent attacks. No association was established between the presence of heterozygous mutations of MEFV and colchicine response.

The evaluation of depression and anxiety levels of mothers of patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome and familial Mediterranean fever

ABSTRACT Objective Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome and familial Mediterranean fever (FMF) are autoinflammatory disorders typically characterized by recurrent fever attacks. These recurrent fever attacks can lead to depression and anxiety in mothers of these patients. This study aimed to compare the depression and anxiety levels in mothers of PFAPA and FMF patients. Methods This study is a cross-sectional observational study. 48 mothers of children with FMF and 70 mothers of children with PFAPA participated in the study. Mothers in these two groups were compared in terms of anxiety and depression by using the validated Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Results Depression and anxiety scores of mothers were found to be similar in FMF and PFAPA groups. Moderate or high level of anxiety was seen in 32% of mothers of patients with PFAPA and 27% of mothers of patients with FMF. 23% of mothers of patients with PFAPA were evaluated as having moderate or severe depression, and 18% of mothers of patients with FMF were evaluated as having moderate depression. There was no statistically significant difference between the duration, frequency of attacks, recurrent hospitalizations, sociodemographic characteristics, and inventory scores. Conclusion Depression and anxiety scores of mothers with children diagnosed with FMF and PFAPA are similar. These two diseases affect families psychosocially at similar levels. It is important to provide psychosocial support to families.

PFAPA syndróm u detí, naša skúsenosť s chirurgickou liečbou – prehľadový článok s kazuistikou

The issue of periodic fever conditions in paediatric patients is connected with wide diff erential dia gnosis. Among other causes, it is necessary to think also about the group of so-called periodic fevers syndrome, or autoinfl ammatory diseases. PFAPA syndrome (Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis syndrome) is the most common representative periodic fever in children’s patients. Eff ective causal treatment of this syndrome is possible within the ENT department. In the article, we provide an overview of PFAPA syndrome among autoinfl ammatory diseases and the eff ect of surgical treatment, tonsillectomy with adenotomy. Key words PFAPA syndrome – periodic fevers – Marshall syndrome – autoinfl ammatory diseases – aphthous stomatitis

Marshall syndrome: A case report

Background. Marshall syndrome, also known as the PFAPA syndrome, is an autoinflammatory disease characterized by periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. This widely common pediatric autoimmune disease often remains undiagnosed due to a lack of knowledge about its clinical features. Therefore, it can be assumed that Marshall syndrome is much more common than it is diagnosed. We describe a clinical case of Marshall syndrome in a five-year-old boy by retrospectively analyzing the patient’s anamnesis, the course of the disease, the results of laboratory and instrumental studies. The treatment approach is also presented. Despite the complexity of this pathology, a positive result in the treatment of the child was achieved. Clinical case description. A five-year-old boy was admitted to the Cardio-Rheumatology Department of the Krasnodar Krai Children’s Regional Clinical Hospital for examination and clarification of the diagnosis. The patient’s parents complained of recurrent episodes of fever. During such episodes, the child’s blood tests revealed leukocytosis, increased erythrocyte sedimentation rate (ESR), and increased C-reactive protein levels. After the end of the episode, all indicators returned to normal levels. The anamnesis showed that, during the previous three months, the boy had been repeatedly hospitalized with various diseases. The preliminary diagnosis was “Juvenile arthritis, systemic variant. Autoinflammatory disease?”. Laboratory studies revealed antineutrophil cytoplasmic antibodies to proteinase-3 (cANCA), to myeloperoxidase (pANCA), and antinuclear antibodies (ANA) in a titer of 1/160. For differential diagnosis, genetic screening for familial Mediterranean fever was performed; however, no mutations in exons two, three, five, and ten of the MEFV gene were found. As a result, the child was diagnosed with “Autoinflammatory disease. Marshall syndrome.” The prescribed therapy with glucocorticosteroid drugs and immunosuppressants produced a positive effect. After recovery, the boy was discharged from the hospital under the supervision of a pediatrician at the place of residence. Conclusion. Difficulties in the treatment of such patients lie, first of all, in the verification of the diagnosis. Indeed, at early stages, the clinical symptoms of monogenic forms of autoinflammatory diseases and other diseases may be similar to Marshall syndrome. As a result, the patients are subjected to unnecessary massive antimicrobial therapy, resulting in deterioration of their quality of life for many years. Untimely diagnosis does not result in an unfavorable outcome or disability due to the benign clinical course of the disease.

Use of Streptococcus Salivarius K12 in a cohort of PFAPA patients.

Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA) is the most common cause of periodic fever in childhood. Although PFAPA is generally a self-limited condition, it can have negative impact on child's and parents' quality of life and family functioning. Our primary aim was to assess the potential effectiveness of Streptococcus Salivarius K12 (SSK12) in preventing febrile attacks in PFAPA patients. Secondary objectives included evaluating the effectiveness of SSK12 in mitigating the severity of febrile episodes seen as a statistically significant reduction in the episode duration, highest fever temperature reached during fever, in the frequency of each associated symptom, calculated in the six months before and after the start of therapy. A total of 117 patients with PFAPA were evaluated using Marshall's criteria, modified by Thomas et al. and according to Eurofever/PRINTO classification criteria, aged 6 months to 9 years, with a median age at the onset of the disease of 2 years, treated with SSK12, since January 2021 to January 2023. Data were collected retrospectively. Before using SS K12, febrile episodes recurred on average every 26.1 ± 11.5 days, with a febrile episode duration of 4.1 ± 1.4 days. The highest fever temperature during the episode was 39.8 ± 0.7 °C. After six months of SS K12, febrile episodes recurred on average every 70 ± 53,1 days (p value <0.01), the mean lenght of febrile episodes was 3.3 ± 1.6 (p value <0.01) and the highest fever temperature reached during the febrile episode was 39.1 ± 1.1 °C (p value <0.01). We also documented a reduction in the frequency of exudative pharyngotonsillitis present in 72 vs. 103 patients (p value <0.01), oral aphthosis present in 47 vs. 80 patients (p value <0.01), lateral cervical lymphadenopathy in 45 vs. 83 (p value <0.01). Erythematous pharyngotonsillitis decreased in frequency but it was not statistically significant. The results of our study indicate that the use of SS K12 could be beneficial in decreasing febrile episodes related to PFAPA syndrome and its associated symptoms, potentially improving the quality of life in pediatric patients and decreasing the need for additional pharmacological therapies.

Sarà veramente PFAPA?

PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis) is the most common periodic fever in childhood. It is a benign self-limiting condition that may resolve spontaneously during the first years of life or within adolescence, although there is increasing evidence of cases that may persist also in adulthood. A small dose of corticosteroids is safe and effective for the management of fever episodes and can also be useful for the diagnosis. Tonsillectomy is a good option for those patients who keep presenting with disabling symptoms after the typical age.

The many faces of pediatric urticaria.

Urticaria is a common disease that can affect individuals of all age groups, with approximately one-quarter of the population experiencing it at least once in their lifetime. Lesions characterized by erythema and itchy hives can appear anywhere on the body. These can vary in size ranging from millimeters to centimeters, and typically clear within 24 h. About 40% of patients with urticaria have accompanying angioedema, which involves localized deep tissue swelling. Urticaria usually occurs spontaneously and is classified into acute and chronic forms, with the latter referring to a condition that lasts for more than 6 weeks. The prevalence of chronic urticaria in the general population ranges from 0.5% to 5%, and it can either be inducible or spontaneous. The most common form of pediatric urticaria is acute and is usually self-limiting. However, a broad differential diagnosis should be considered in children with urticaria, particularly if they also have accompanying systemic complaints. Differential diagnoses of pediatric urticaria include chronic spontaneous urticaria, chronic inducible urticaria, serum sickness-like reaction, urticarial vasculitis, and mast cell disorders. Conditions that can mimic urticaria, including but not limited to cryopyrinopathies, hyper IgD syndrome, Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis (PFAPA), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPs), and Schnitzler syndrome should also be considered. The many faces of pediatric urticaria can be both easy and confusing. A pragmatic approach relies on clinical foresight and understanding the various forms of urticaria and their potential mimickers. This approach can pave the way for an accurate and optimized diagnostic approach in children with urticaria.

The effect of vitamin D supplementation on attacks in PFAPA syndrome patients with low vitamin D levels.

To evaluate the effect of vitamin D supplementation on the frequency and duration of attacks in patients of PFAPA syndrome with low vitamin D levels. This retrospective study comprised PFAPA patients with vitamin D deficiency/insufficiency between 2018 and 2023. The frequency and duration of PFAPA attacks before and after vitamin D supplementation were noted. Seventy-one patients were included. Of the 71 patients, 24 (33.8%) had vitamin D insufficiency, and 47 (66.2%) had vitamin D deficiency. In patients with vitamin D insufficiency, mean attack frequency and mean attack duration before vitamin D supplementation were 4.3 ± 1.9/year and 2.2 ± 1.6days, respectively, while mean attack frequency and mean attack duration after vitamin D supplementation were 3.5 ± 2.7/year per year and 1.3 ± 0.9days respectively (p = 0.2, p = 0.2, respectively). In patients with vitamin D deficiency, mean attack frequency and mean attack duration before vitamin D supplementation were 7.4 ± 2.1/year and 2.2 ± 1.6days, respectively, while mean attack frequency and mean attack duration after vitamin D supplementation were 3.3 ± 2.4/year and 1.3 ± 0.9days respectively (p < 0.01, p = 0.04, respectively). When the vitamin D level and the frequency of attacks were compared, the cut-off value of vitamin D was found to be 29.7nmol/L. In PFAPA patients with low vitamin D levels, the frequency and duration of PFAPA attacks were reduced with vitamin D supplementation. Especially at vitamin D level cut-off > 29.7nmol/L, the frequency of attacks reduced significantly.

PFAPA syndrome in children.

Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome is, as the name implies, characterized by an extremely regular cycle of fevers that is accompanied by one or more other symptoms such as oral ulcers, pharyngitis, adenitis, tonsillitis, sore throat, cervical adenopathy, and headache. Originally known as Marshall syndrome, PFAPA is most commonly identified in children younger than age 5 years; however, adults may also present with the disease, though they may report additional symptoms. PFAPA is now understood to be a diagnosis of exclusion. Laboratory studies are typically unremarkable except for increases in acute phase reactants such as C-reactive protein. Treatment is primarily supportive and most frequently uses systemic steroids to suppress the inflammatory response. Acute flares are self-limited, and the syndrome typically resolves on its own as the child reaches age 7 or 8 years.

Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience.

Despite the advanced knowledge concerning autoinflammatory diseases (AID), more data regarding the optimal treatment options and outcomes of the children who met the criteria of more than one AID are required. This study aimed to describe the demographic and clinical characteristics of children from familial Mediterranean fever (FMF)-endemic countries who meet both the FMF and the periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome criteria. Moreover, we aimed to measure the response rates to colchicine and tonsillectomy and evaluate the factors affecting the colchicine response in these patients. The study was conducted at pediatric rheumatology tertiary centre. A total of 131 patients (58 females; 73 males) who met both the modified Marshall and pediatric FMF criteria were included. The median age at onset was 18months (1-77months), and the mean age at diagnosis was 47 ± 21.88months. The median interval between episodes was 21 (7-90) days. The median disease duration was 46 (6-128) months. Consanguineous marriage was detected in 17 (13%) of the patients. The most common clinical finding was fever (100%), followed by exudative pharyngitis (88.5%), abdominal pain (86.3%), arthralgia (61.8%), stomatitis (51.1%), adenitis (42%), myalgia (28.7%), chest pain (16%), maculopapular rash (12.2%), arthritis (8.4%), and erysipelas-like rash (4.6%). MEFV gene variants were identified in 106 (80.9%) patients. The most common variants were M694V heterozygous (29%). We found that patients with tonsillopharyngitis, aphthous stomatitis, and PFAPA family history were more likely to be colchicine-resistant and tonsillectomy responsive, while those with exon 10 MEFV gene mutations were more prone to have a favorable response to colchicine. Conclusion: PFAPA syndrome patients with exon 10 MEFV gene mutation, showing typical FMF symptoms, should be treated with colchicine, even after tonsillectomy. In multivariate analysis, PFAPA family history and lack of exon 10 MEFV gene mutations were independent risk factors for colchicine resistance. Thus, tonsillectomy may be recommended as a possible treatment option for these patients. It has yet to be clarified when colchicine treatment will be discontinued in patients whose attacks ceased after tonsillectomy that was performed due to colchicine unresponsiveness. What is Known: • A certain number of patients with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome concomitantly fulfill the familial Mediterranean fever (FMF) criteria. • While colchicine is proposed as a first treatment choice in familial Mediterranean fever (FMF), corticosteroids are recommended as a first-line treatment in PFAPA syndrome patients. What is New: • In patients with concomitant PFAPA syndrome and FMF, PFAPA family history and lack of exon 10 MEFV gene mutation are predictive factors of colchicineresistance. • The presence of exon 10 MEFV gene mutations in patients with concomitant FMF and PFAPA syndrome has a favourable effect on response to colchicine treatment.

Childhood PFAPA Syndrome Cases in a University Hospital in Turkey: A 10-Year Analysis

Amaç: Ateş, aftöz stomatit, farenjit ve servikal adenit (PFAPA) sendromu , üç ana belirtiden en az biriyle ilişkili, her 3-6 haftada bir tekrarlayan, 3-6 gün süren ateş atakları ile karakterizedir. Bu çalışmada, PFAPA sendromu hastalığının demografik, klinik özellikleri,laboratuvar bulguları ve uygulanan tedavinin etkinliğinin değerlendirilmesi amaçlanmıştır.&#x0D; Gereç ve Yöntemler: Bu çalışmaya Sivas Cumhuriyet Üniversitesi Hastahanesi Pediatri Polikliniğine 01.01.2012-31.12.2022 tarihleri arasında başvuran 0-18 yaş grubu hastalardan PFAPA Sendromu tanısı alan 73 hasta dahil edildi. Çalışmaya dahil edilecek hastalarda yaş, cinsiyet gibi demografik verileri, semptomlar, laboratuvar bulguları, uygulanan tedavi ve tedavinin etkinliği incelendi.&#x0D; Bulgular: Yetmiş üç hastanın 34’ü (%46,6) kız , 39’u (%53,4) erkekti. Ortalama ve medyan tanı yaşı ise sırasıyla 3,85±1,47 yıl ve 3,30 (1,1–7,5) yıldı. En yaygın başvuru şikayeti ateş idi. 73 hastadan 64’ünde (%87,6) ateş şikayeti mevcuttu. Hastaların 56’sında (%76,7) farenjit, 26’sında (%35,6) servikal lenfadenit, 12’sinde (%16,5) kriptik tonsilit, 15’inde (%20,6) aftöz stomatit mevcuttu. Tanı anında hastalarda lökopeni ve nötropeni saptanmadı. Nötrofil yüksekliği 59 (%80,8) hastada ve lökositoz 64 (%87,7) hastada görüldü. Tedavi öncesi tüm hastaların CRP değeri referans değeri olan 8 mg/L’den yüksek bulundu. Tedavi öncesi ESH değeri hastaların 10 (% 13,7)’unda normal değerlerde (20 mm/h’den düşük), 63 (% 86,3) hastada ise 20 mm/h’den yüksekti. 73 hastadan 10’una (%13,7) tonsillektomi uygulandı.&#x0D; Tartışma ve Sonuç: Tekrarlayan ateş ve tonsilit atakları ile getirilen, antibiyotik tedavisine rağmen ateşi düşmeyen 5 yaşından küçük hastalarda ayırıcı tanıda PFAPA sendromu olasılığı göz önünde bulundurulmalıdır. Bu sayede erken tanı konabilir, gereksiz antibiyotik kullanımından kaçınılabilir ve böylelikle gereksiz tetkik, tedavi ve hastaneye yatışların önüne geçilebilir.

Variables fordifferential diagnosis offamilial Mediterranean fever: Multiple correspondence analysis ofa large Japanese cohort.

We investigated differential diagnoses that should be noted with familial Mediterranean fever (FMF) and useful variables for differentiation in a large Japanese cohort. Patients aged ≥13 years who were clinically suspected of having FMF by Livneh criteria were studied 1 year after MEFV genetic testing. Patients ultimately diagnosed with other diseases were studied, and the association among each disease, patient characteristics, and clinical variables were analysed using multiple correspondence analysis. In total, 504 patients were included in this study; 34 (6.7%) were diagnosed with a disease other than FMF. The most common diagnosis was Behçet's disease, followed by periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome, inflammatory bowel disease, myelodysplastic syndromes (MDS), and infectious diseases. Although none of the non-FMF patients had exon 10 variants, some responded to colchicine treatment. Multiple correspondence analysis suggested that atypical symptoms such as stomatitis were associated with Behçet's disease and PFAPA syndrome, whereas characteristic situations such as disease onset ≥40 years were associated with MDS and infectious diseases. Careful follow-ups and reanalysis of the diagnosis should be performed for patients with atypical findings and no exon 10 variants, even if their symptoms meet the clinical criteria for FMF.

NLRP12-associated autoinflammatory disease: much more than the FCAS phenotype.

NLRP12-associated autoinflammatory disease (NLRP12-AID) is a rarely seen periodic fever syndrome also known as familial cold autoinflammatory syndrome-2 (FCAS2), caused by autosomal dominant inherited mutations in the NLRP12 gene. We aimed to present our clinical experience constituting one of the largest paediatric NLRP12-AID cohort. The patients with preliminary diagnosis of systemic autoinflammatory disease (SAID) other than familial Mediterranean fever (FMF) and PFAPA syndrome were evaluated with the next-generation-sequence (NGS) genetic-panel analysis between January-2016 and January-2022. Among children carrying NLRP12-variant, patients with recurrent episodes of autoinflammatory disease manifestations were diagnosed with NLRP12-AID. Demographic, clinical and laboratory data, treatments and outcomes of patients were presented. Seventeen patients were diagnosed with NLRP12-AID. The mean age at diagnosis was 114.7±69.5 months. The most frequently seen clinical manifestations were respectively; fever (100%), arthritis/arthralgia (58.8%), rash (52.9%), abdominal pain (52.9%), diarrhoea (41.2%), myalgia/fatigue (53.2%) and, conjunctivitis (11.7%). Clinical manifestations were triggered by cold exposure in three patients (17.6%). Seven patients had pathogenic, one had likely pathogenic, seven had VUS, and two had novel heterozygous variants. The most common defined variant in the NLRP12 gene was R352C. Complete response was achieved in 5 patients and partial response was in 6 with colchicine treatment. Attacks were prevented with anti-IL-1 treatments in 6 patients unresponsive to colchicine. In conclusion, the disease can cause effects on various tissues, especially the musculoskeletal and gastrointestinal systems, apart from FCAS symptoms. We think that a patient who can be defined as syndrome of undifferentiated recurrent fever should also be evaluated genetically in terms of NLRP12 previously.

PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, (PFAPA) SYNDROME AND NLRP3 GENE ASSOCIATION

PFAPA syndrome, which also includes aphthous stomatitis, pharyngitis, and adenitis, is the most common type of recurrent fever in children. Usually happens before the age of five. This syndrome is characterized by attacks lasting 3-7 days, recurring every 2-8 weeks with high fever (39 C and above) accompanied by at least one of the signs of aphthous stomatitis, pharyngitis, and/or cervical adenitis. Between attacks, the child is completely healthy.PFAPA is a benign disease that regresses with age. Steroids are used in the treatment of attacks. Colchicine is often preferred in prophylactic treatment. However, if there is no response to medical treatment, surgery (tonsillectomy) can be performed. Genetic and environmental factors are considered in the etiology. Genetic susceptibility concentrated on the genes for Familiar Mediterranean Fever (FMF, MEFV), TNF-Receptor-Associated Periodic Syndrome (TRAPS, gene TNFRF1A), HyperIgDSyndrome (HIDS, gene MVK), and Cryopyrin-Associated Periodic Syndrome (CAPS, gene NLRP3). But its etiology is still unknown.

Tonsillectomy reduces the family impact of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome and improves health-related quality of life in affected children

BackgroundPeriodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome is an autoinflammatory disorder that primarily affects young children, and typically gives rise to fever episodes that recur monthly for several years. This study investigated the impact of PFAPA syndrome on the families of affected children, the health-related quality of life (HRQOL) of children with the syndrome, and how these factors were influenced by tonsillectomy.MethodsThis prospective cohort study included 24 children with typical PFAPA syndrome that were referred for tonsillectomy, of whom 20 underwent the procedure. The control group consisted of randomly selected children from the general population. Family impact and HRQOL were measured using the standardized, validated questionnaires Pediatric Quality of Life Inventory™ (PedsQL™) Family Impact Module (FIM) and PedsQL™ 4.0 Generic Core Scales (GCS). Parents to children with PFAPA completed the questionnaires before and 6 months after their child underwent tonsillectomy, and HRQOL was measured both between and during PFAPA episodes. The Wilcoxon signed-rank test was used to compare data before and after tonsillectomy in the patient group, while the Mann–Whitney test was used for comparison of the patient and control groups.ResultsBefore tonsillectomy, children with PFAPA had significantly lower scores than the control group on the PedsQL™ FIM and the PedsQL™ 4.0 GCS during fever episodes. After tonsillectomy, all patients improved with diminished febrile episodes, which resulted in significantly higher scores regarding both family impact and HRQOL at the time of follow-up. HRQOL of in children with PFAPA improved after tonsillectomy even when compared to afebrile intervals before the procedure. The differences between PFAPA patients and controls were eliminated after tonsillectomy.ConclusionPFAPA syndrome has a profound negative impact on the families of affected children. Tonsillectomy that leads to cessation or reduction of fever episodes eases the impact of the disease on the family. HRQOL in children with PFAPA is low during febrile episodes and similar to healthy controls in between episodes. The improvement of HRQOL in patients with PFAPA after tonsillectomy compared to the afebrile intervals before tonsillectomy highlights that the constantly recurring fevers may affect the children’s well-being even between fever episodes.